{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:01:17Z","timestamp":1791896477677,"version":"4.3.4"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1038\/s41573-020-0078-4","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T23:07:40Z","timestamp":1599001660000},"page":"695-710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Soluble ligands as drug targets"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1832-7728","authenticated-orcid":false,"given":"Misty M.","family":"Attwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rgen","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8008-4659","authenticated-orcid":false,"given":"Mathias","family":"Rask-Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7112-0921","authenticated-orcid":false,"given":"Helgi B.","family":"Schi\u00f6th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"78_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1146\/annurev-pharmtox-011613-135943","volume":"54","author":"M Rask-Andersen","year":"2014","unstructured":"Rask-Andersen, M., Masuram, S. & Schi\u00f6th, H. B. The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu. Rev. Pharmacol. Toxicol. 54, 9\u201326 (2014).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"78_CR2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.tips.2018.03.003","volume":"39","author":"MM Attwood","year":"2018","unstructured":"Attwood, M. M., Rask-Andersen, M. & Schi\u00f6th, H. B. Orphan drugs and their impact on pharmaceutical development. Trends Pharmacol. Sci. 39, 525\u2013535 (2018).","journal-title":"Trends Pharmacol. Sci."},{"key":"78_CR3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrd892","volume":"1","author":"AL Hopkins","year":"2002","unstructured":"Hopkins, A. L. & Groom, C. R. The druggable genome. Nat. Rev. Drug Discov. 1, 727\u2013730 (2002).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78_CR4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nrd2199","volume":"5","author":"JP Overington","year":"2006","unstructured":"Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are there? Nat. Rev. Drug Discov. 5, 993\u2013996 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78_CR5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","volume":"16","author":"R Santos","year":"2017","unstructured":"Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19\u201334 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78_CR6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/bab.1617","volume":"65","author":"M Kesik\u2010Brodacka","year":"2017","unstructured":"Kesik-Brodacka, M. Progress in biopharmaceutical development. Biotechnol. Appl. Biochem. 65, 306\u2013322 (2017).","journal-title":"Biotechnol. Appl. Biochem."},{"key":"78_CR7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/d41573-019-00049-0","volume":"18","author":"L Urquhart","year":"2019","unstructured":"Urquhart, L. Top drugs and companies by sales in 2018. Nat. Rev. Drug Discov. 18, 245\u2013245 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78_CR8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/d41573-020-00047-7","volume":"19","author":"L Urquhart","year":"2020","unstructured":"Urquhart, L. Top companies and drugs by sales in 2019. Nat. Rev. Drug Discov. 19, 228\u2013228 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","volume":"27","author":"R-M Lu","year":"2020","unstructured":"Lu, R.-M. et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 27, 1 (2020).","journal-title":"J. Biomed. Sci."},{"key":"78_CR10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4161\/mabs.2.2.11360","volume":"2","author":"LA Sullivan","year":"2010","unstructured":"Sullivan, L. A. & Brekken, R. A. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2, 165\u2013175 (2010).","journal-title":"MAbs"},{"key":"78_CR11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3858\/emm.2011.43.10.063","volume":"43","author":"H Shim","year":"2011","unstructured":"Shim, H. One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Exp. Mol. Med. 43, 539\u2013549 (2011).","journal-title":"Exp. Mol. Med."},{"key":"78_CR12","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/gt.2012.17","volume":"19","author":"M Giacca","year":"2012","unstructured":"Giacca, M. & Zacchigna, S. VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. Gene Ther. 19, 622\u2013629 (2012).","journal-title":"Gene Ther."},{"key":"78_CR13","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","volume":"20","author":"RNVS Suragani","year":"2014","unstructured":"Suragani, R. N. V. S. et al. Transforming growth factor-\u03b2 superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat. Med. 20, 408\u2013414 (2014).","journal-title":"Nat. Med."},{"key":"78_CR14","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula, J. T. et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol. Med. 8, 1265\u20131288 (2016).","journal-title":"EMBO Mol. Med."},{"key":"78_CR15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrneph.2017.156","volume":"14","author":"D Ricklin","year":"2018","unstructured":"Ricklin, D., Mastellos, D. C., Reis, E. S. & Lambris, J. D. The renaissance of complement therapeutics. Nat. Rev. Nephrol. 14, 26\u201347 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"78_CR16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxu102","volume":"27","author":"C Monaco","year":"2015","unstructured":"Monaco, C., Nanchahal, J., Taylor, P. & Feldmann, M. Anti-TNF therapy: past, present and future. Int. Immunol. 27, 55\u201362 (2015).","journal-title":"Int. Immunol."},{"key":"78_CR17","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte, R. S., Chen, D. S. & Ferrara, N. VEGF in signaling and disease: beyond discovery and development. Cell 176, 1248\u20131264 (2019).","journal-title":"Cell"},{"key":"78_CR18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.phrs.2015.11.027","volume":"103","author":"M Amadio","year":"2016","unstructured":"Amadio, M., Govoni, S. & Pascale, A. Targeting VEGF in eye neovascularization: what\u2019s new?: a comprehensive review on current therapies and oligonucleotide-based interventions under development. Pharmacol. Res. 103, 253\u2013269 (2016).","journal-title":"Pharmacol. Res."},{"key":"78_CR19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrd4518","volume":"14","author":"HS Bartlett","year":"2015","unstructured":"Bartlett, H. S. & Million, R. P. Targeting the IL-17\u2013TH17 pathway. Nat. Rev. Drug Discov. 14, 11\u201312 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78_CR20","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes, J. E., Yan, B. Y., Chan, T. C. & Krueger, J. G. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J. Immunol. 201, 1605\u20131613 (2018).","journal-title":"J. Immunol."},{"key":"78_CR21","unstructured":"FDA. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. http:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-osteoporosis-postmenopausal-women-high-risk-fracture (2019)."},{"key":"78_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jot.2015.08.004","volume":"4","author":"PK Suen","year":"2016","unstructured":"Suen, P. K. & Qin, L. Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: a general review. J. Orthop. Translat. 4, 1\u201313 (2016).","journal-title":"J. Orthop. Translat."},{"key":"78_CR23","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s40265-018-1004-5","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy, S. M. Fremanezumab: first global approval. Drugs 78, 1829\u20131834 (2018).","journal-title":"Drugs"},{"key":"78_CR24","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s40265-018-1002-7","volume":"78","author":"YN Lamb","year":"2018","unstructured":"Lamb, Y. N. Galcanezumab: first global approval. Drugs 78, 1769\u20131775 (2018).","journal-title":"Drugs"},{"key":"78_CR25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40265-020-01300-4","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S. Eptinezumab: first approval. Drugs 80, 733\u2013739 (2020).","journal-title":"Drugs"},{"key":"78_CR26","doi-asserted-by":"crossref","unstructured":"Edvinsson, L. in Calcitonin Gene-Related Peptide (CGRP) Mechanisms: Focus on Migraine (eds Brain, S. D. & Geppetti, P.) 121\u2013130 (Springer, 2019).","DOI":"10.1007\/164_2018_201"},{"key":"78_CR27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/head.13305","volume":"58","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson, L. The CGRP pathway in migraine as a viable target for therapies. Headache J. Head Face Pain 58, 33\u201347 (2018).","journal-title":"Headache J. Head Face Pain"},{"key":"78_CR28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.xphs.2019.05.031","volume":"109","author":"DR Goulet","year":"2019","unstructured":"Goulet, D. R. & Atkins, W. M. Considerations for the design of antibody-based therapeutics. J. Pharm. Sci. 109, 74\u2013103 (2019).","journal-title":"J. Pharm. Sci."},{"key":"78_CR29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4161\/mabs.3.3.15234","volume":"3","author":"T Igawa","year":"2011","unstructured":"Igawa, T. et al. Engineering the variable region of therapeutic IgG antibodies. MAbs 3, 243\u2013252 (2011).","journal-title":"MAbs"},{"key":"78_CR30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40259-016-0174-5","volume":"30","author":"C Pineda","year":"2016","unstructured":"Pineda, C., Casta\u00f1eda Hern\u00e1ndez, G., Jacobs, I. A., Alvarez, D. F. & Carini, C. Assessing the immunogenicity of biopharmaceuticals. BioDrugs 30, 195\u2013206 (2016).","journal-title":"BioDrugs"},{"key":"78_CR31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","volume":"157","author":"P Chames","year":"2009","unstructured":"Chames, P., Regenmortel, M. V., Weiss, E. & Baty, D. Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 157, 220\u2013233 (2009).","journal-title":"Br. J. Pharmacol."},{"key":"78_CR32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.coi.2016.03.002","volume":"40","author":"RJ Brezski","year":"2016","unstructured":"Brezski, R. J. & Georgiou, G. Immunoglobulin isotype knowledge and application to Fc engineering. Curr. Opin. Immunol. 40, 62\u201369 (2016).","journal-title":"Curr. Opin. Immunol."},{"key":"78_CR33","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coi.2016.03.005","volume":"40","author":"P Sondermann","year":"2016","unstructured":"Sondermann, P. & Szymkowski, D. E. Harnessing Fc receptor biology in the design of therapeutic antibodies. Curr. Opin. Immunol. 40, 78\u201387 (2016).","journal-title":"Curr. Opin. Immunol."},{"key":"78_CR34","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1074\/jbc.M110277200","volume":"277","author":"S Tridandapani","year":"2002","unstructured":"Tridandapani, S. et al. Regulated expression and inhibitory function of Fc\u03b3RIIb in human monocytic cells. J. Biol. Chem. 277, 5082\u20135089 (2002).","journal-title":"J. Biol. Chem."},{"key":"78_CR35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd3365","volume":"10","author":"X-R Jiang","year":"2011","unstructured":"Jiang, X.-R. et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat. Rev. Drug Discov. 10, 101\u2013111 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78_CR36","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A. & Bell, L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 25, 1256\u20131264 (2007).","journal-title":"Nat. Biotechnol."},{"key":"78_CR37","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1080\/07388551.2017.1357002","volume":"38","author":"PJ Kennedy","year":"2018","unstructured":"Kennedy, P. J., Oliveira, C., Granja, P. L. & Sarmento, B. Monoclonal antibodies: technologies for early discovery and engineering. Crit. Rev. Biotechnol. 38, 394\u2013408 (2018).","journal-title":"Crit. Rev. Biotechnol."},{"key":"78_CR38","first-page":"0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan, D. et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS ONE 13, 0195909 (2018).","journal-title":"PLoS ONE"},{"key":"78_CR39","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2125.2011.03958.x","volume":"71","author":"EA Dubois","year":"2011","unstructured":"Dubois, E. A., Rissmann, R. & Cohen, A. F. Rilonacept and canakinumab. Br. J. Clin. Pharmacol. 71, 639\u2013641 (2011).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"78_CR40","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/bjophthalmol-2011-300654","volume":"96","author":"MW Stewart","year":"2012","unstructured":"Stewart, M. W. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br. J. Ophthalmol. 96, 1157\u20131158 (2012).","journal-title":"Br. J. Ophthalmol."},{"key":"78_CR41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1060028013506562","volume":"48","author":"SL Perkins","year":"2014","unstructured":"Perkins, S. L. & Cole, S. W. Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer. Ann. Pharmacother. 48, 93\u201398 (2014).","journal-title":"Ann. Pharmacother."},{"key":"78_CR42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4161\/mabs.23684","volume":"5","author":"DK Shah","year":"2013","unstructured":"Shah, D. K. & Betts, A. M. Antibody biodistribution coefficients. MAbs 5, 297\u2013305 (2013).","journal-title":"MAbs"},{"key":"78_CR43","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/antib8020028","volume":"8","author":"A Bates","year":"2019","unstructured":"Bates, A. & Power, C. A. David vs. Goliath: the structure, function, and clinical prospects of antibody fragments. Antibodies 8, 28 (2019).","journal-title":"Antibodies"},{"key":"78_CR44","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","volume":"8","author":"P Bannas","year":"2017","unstructured":"Bannas, P., Hambach, J. & Koch-Nolte, F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Front Immunol 8, 1603 (2017).","journal-title":"Front Immunol"},{"key":"78_CR45","unstructured":"FDA. FDA approved caplacizumab-yhdp. http:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approved-caplacizumab-yhdp (2019)."},{"key":"78_CR46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40291-019-00400-6","volume":"23","author":"SK Ha\u00dfel","year":"2019","unstructured":"Ha\u00dfel, S. K. & Mayer, G. Aptamers as therapeutic agents: has the initial euphoria subsided? Mol. Diagn. Ther. 23, 301\u2013309 (2019).","journal-title":"Mol. Diagn. Ther."},{"key":"78_CR47","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev-pharmtox-010716-104558","volume":"57","author":"SM Nimjee","year":"2017","unstructured":"Nimjee, S. M., White, R. R., Becker, R. C. & Sullenger, B. A. Aptamers as therapeutics. Annu. Rev. Pharmacol. Toxicol. 57, 61\u201379 (2017).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"78_CR48","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.3390\/ijms20102511","volume":"20","author":"MH Ali","year":"2019","unstructured":"Ali, M. H., Elsherbiny, M. E. & Emara, M. Updates on aptamer research. Int. J. Mol. Sci. 20, 2511 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"78_CR49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","volume":"5","author":"EWM Ng","year":"2006","unstructured":"Ng, E. W. M. et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5, 123\u2013132 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78_CR50","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/mtm.2016.14","volume":"5","author":"KE Maier","year":"2016","unstructured":"Maier, K. E. & Levy, M. From selection hits to clinical leads: progress in aptamer discovery. Mol. Ther. Methods Clin. Dev. 5, 16014 (2016).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"78_CR51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/cancers10030080","volume":"10","author":"Y Morita","year":"2018","unstructured":"Morita, Y., Leslie, M., Kameyama, H., Volk, D. E. & Tanaka, T. Aptamer therapeutics in cancer: current and future. Cancers 10, 80 (2018).","journal-title":"Cancers"},{"key":"78_CR52","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-anchem-061516-045205","volume":"10","author":"X Yu","year":"2017","unstructured":"Yu, X., Yang, Y.-P., Dikici, E., Deo, S. K. & Daunert, S. Beyond antibodies as binding partners: the role of antibody mimetics in bioanalysis. Annu. Rev. Anal. Chem. 10, 293\u2013320 (2017).","journal-title":"Annu. Rev. Anal. Chem."},{"key":"78_CR53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13238-017-0386-6","volume":"9","author":"R Simeon","year":"2018","unstructured":"Simeon, R. & Chen, Z. In vitro-engineered non-antibody protein therapeutics. Protein Cell 9, 3\u201314 (2018).","journal-title":"Protein Cell"},{"key":"78_CR54","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","volume":"55","author":"A Pl\u00fcckthun","year":"2015","unstructured":"Pl\u00fcckthun, A. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu. Rev. Pharmacol. Toxicol. 55, 489\u2013511 (2015).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"78_CR55","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10456-012-9302-0","volume":"16","author":"A Stahl","year":"2013","unstructured":"Stahl, A. et al. Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. Angiogenesis 16, 101\u2013111 (2013).","journal-title":"Angiogenesis"},{"key":"78_CR56","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.35","volume":"49","author":"FY Frejd","year":"2017","unstructured":"Frejd, F. Y. & Kim, K.-T. Affibody molecules as engineered protein drugs. Exp. Mol. Med. 49, e306 (2017).","journal-title":"Exp. Mol. Med."},{"key":"78_CR57","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fonc.2019.00297","volume":"9","author":"R Goswami","year":"2019","unstructured":"Goswami, R. et al. Gene therapy leaves a vicious cycle. Front. Oncol. 9, 297 (2019).","journal-title":"Front. Oncol."},{"key":"78_CR58","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymthe.2018.11.003","volume":"27","author":"R Grishanin","year":"2019","unstructured":"Grishanin, R. et al. Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration. Mol. Ther. 27, 118\u2013129 (2019).","journal-title":"Mol. Ther."},{"key":"78_CR59","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3390\/genes9120575","volume":"9","author":"DJ Jiang","year":"2018","unstructured":"Jiang, D. J., Xu, C. L. & Tsang, S. H. Revolution in gene medicine therapy and genome surgery. Genes 9, 575 (2018).","journal-title":"Genes"},{"key":"78_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-316195","author":"TAC Guimaraes","year":"2020","unstructured":"Guimaraes, T. A. C., de, Georgiou, M., Bainbridge, J. W. B. & Michaelides, M. Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions. Br. J. Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316195 (2020).","journal-title":"Br. J. Ophthalmol."},{"key":"78_CR61","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","volume":"70","author":"XM Anguela","year":"2019","unstructured":"Anguela, X. M. & High, K. A. Entering the modern era of gene therapy. Annu. Rev. Med. 70, 273\u2013288 (2019).","journal-title":"Annu. Rev. Med."},{"key":"78_CR62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-019-0103-y","volume":"4","author":"RE Hollingsworth","year":"2019","unstructured":"Hollingsworth, R. E. & Jansen, K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines 4, 1\u201310 (2019).","journal-title":"NPJ Vaccines"},{"key":"78_CR63","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1161\/HYPERTENSIONAHA.118.11084","volume":"72","author":"H Nakagami","year":"2018","unstructured":"Nakagami, H. & Morishita, R. Recent advances in therapeutic vaccines to treat hypertension. Hypertension 72, 1031\u20131036 (2018).","journal-title":"Hypertension"},{"key":"78_CR64","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.jtho.2016.08.132","volume":"11","author":"R Rosell","year":"2016","unstructured":"Rosell, R. et al. Pathway targeted immunotherapy: rationale and evidence of durable clinical responses with a novel, EGF-directed agent for advanced NSCLC. J. Thorac. Oncol. 11, 1954\u20131961 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"78_CR65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","volume":"57","author":"CF Bennett","year":"2017","unstructured":"Bennett, C. F., Baker, B. F., Pham, N., Swayze, E. & Geary, R. S. Pharmacology of antisense drugs. Annu. Rev. Pharmacol. Toxicol. 57, 81\u2013105 (2017).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"78_CR66","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten, R. L., Rossi, J. J. & Han, S. The current state and future directions of RNAi-based therapeutics. Nat. Rev. Drug Discov. 18, 421\u2013446 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78_CR67","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole, R. & Slack, F. J. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 16, 203\u2013222 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78_CR68","doi-asserted-by":"crossref","first-page":"PL01.002","DOI":"10.1212\/WNL.86.16_supplement.PL01.002","volume":"86","author":"B Leavitt","year":"2016","unstructured":"Leavitt, B. et al. Discovery and early clinical development of ISIS-HTTRx, the first HTT-lowering drug to be tested in patients with Huntington\u2019s disease (PL01.002). Neurology 86, PL01.002 (2016).","journal-title":"Neurology"},{"key":"78_CR69","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.omtn.2017.06.005","volume":"8","author":"C Chakraborty","year":"2017","unstructured":"Chakraborty, C., Sharma, A. R., Sharma, G., Doss, C. G. P. & Lee, S.-S. Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine. Mol. Ther. Nucleic Acids 8, 132\u2013143 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"78_CR70","doi-asserted-by":"crossref","DOI":"10.1097\/01.hjh.0000548056.97306.34","volume":"36","author":"E Uijl","year":"2018","unstructured":"Uijl, E. et al. A3941 long-lasting small interfering RNA targeting angiotensinogen induces a robust and durable antihypertensive effect. J. Hypertens. 36, e17 (2018).","journal-title":"J. Hypertens."},{"key":"78_CR71","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1038\/onc.2012.305","volume":"32","author":"PM Neilsen","year":"2013","unstructured":"Neilsen, P. M. et al. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene 32, 2992\u20133000 (2013).","journal-title":"Oncogene"},{"key":"78_CR72","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood.V128.22.1829.1829","volume":"128","author":"C Querfeld","year":"2016","unstructured":"Querfeld, C. et al. Preliminary results of a phase 1 trial evaluating MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155, in patients with CTCL. Blood 128, 1829\u20131829 (2016).","journal-title":"Blood"},{"key":"78_CR73","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cbpa.2017.03.010","volume":"38","author":"JW Kim","year":"2017","unstructured":"Kim, J. W. & Cochran, J. R. Targeting ligand\u2013receptor interactions for development of cancer therapeutics. Curr. Opin. Chem. Biol. 38, 62\u201369 (2017).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"78_CR74","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nbt.2291","volume":"30","author":"CG Sandercock","year":"2012","unstructured":"Sandercock, C. G. & Storz, U. Antibody specification beyond the target: claiming a later-generation therapeutic antibody by its target epitope. Nat. Biotechnol. 30, 615\u2013618 (2012).","journal-title":"Nat. Biotechnol."},{"key":"78_CR75","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41232-016-0015-4","volume":"36","author":"S Nakayamada","year":"2016","unstructured":"Nakayamada, S. & Tanaka, Y. BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. Inflamm. Regen. 36, 6 (2016).","journal-title":"Inflamm. Regen."},{"key":"78_CR76","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.334","volume":"6","author":"H Matsumoto","year":"2015","unstructured":"Matsumoto, H. et al. Membrane-bound and soluble Fas ligands have opposite functions in photoreceptor cell death following separation from the retinal pigment epithelium. Cell Death Dis. 6, e1986 (2015).","journal-title":"Cell Death Dis."},{"key":"78_CR77","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.38617","volume":"66","author":"MC Genovese","year":"2014","unstructured":"Genovese, M. C. et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol. 66, 1693\u20131704 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"78_CR78","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/ar4347","volume":"15","author":"DA Martin","year":"2013","unstructured":"Martin, D. A. et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res. Ther. 15, R164 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"78_CR79","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3899\/jrheum.141271","volume":"42","author":"K Pavelka","year":"2015","unstructured":"Pavelka, K. et al. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J. Rheumatol. 42, 912\u2013919 (2015).","journal-title":"J. Rheumatol."},{"key":"78_CR80","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.molmed.2016.01.001","volume":"22","author":"A Beringer","year":"2016","unstructured":"Beringer, A., Noack, M. & Miossec, P. IL-17 in chronic inflammation: from discovery to targeting. Trends Mol. Med. 22, 230\u2013241 (2016).","journal-title":"Trends Mol. Med."},{"key":"78_CR81","unstructured":"FDA. FDA approves novel preventive treatment for migraine. http:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-novel-preventive-treatment-migraine (2019)."},{"key":"78_CR82","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","volume":"21","author":"D Przepiorka","year":"2015","unstructured":"Przepiorka, D. et al. FDA approval: blinatumomab. Clin. Cancer Res. 21, 4035\u20134039 (2015).","journal-title":"Clin. Cancer Res."},{"key":"78_CR83","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. W. H. I. Bispecific antibodies: a mechanistic review of the pipeline. Nat. Rev. Drug Discov. 18, 585\u2013608 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78_CR84","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","volume":"9","author":"U Brinkmann","year":"2017","unstructured":"Brinkmann, U. & Kontermann, R. E. The making of bispecific antibodies. MAbs 9, 182\u2013212 (2017).","journal-title":"MAbs"},{"key":"78_CR85","first-page":"666","volume":"16","author":"A Mullard","year":"2017","unstructured":"Mullard, A. Bispecific antibody pipeline moves beyond oncology. Nat. Rev. Drug Discov. 16, 666\u2013668 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78_CR86","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10637-018-0665-y","volume":"37","author":"A Jimeno","year":"2019","unstructured":"Jimeno, A. et al. A first-in-human phase 1a study of the bispecific anti-DLL4\/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Invest. New Drugs 37, 461\u2013472 (2019).","journal-title":"Invest. New Drugs"},{"key":"78_CR87","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/19420862.2016.1248012","volume":"9","author":"TJ Egan","year":"2016","unstructured":"Egan, T. J. et al. Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments. MAbs 9, 68\u201384 (2016).","journal-title":"MAbs"},{"key":"78_CR88","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","volume":"10","author":"AD Levin","year":"2016","unstructured":"Levin, A. D., Wildenberg, M. E., Brink, V. D. & R, G. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J. Crohns Colitis 10, 989\u2013997 (2016).","journal-title":"J. Crohns Colitis"},{"key":"78_CR89","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","volume":"121","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn, W. J. et al. Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121, 1088\u20131094 (2001).","journal-title":"Gastroenterology"},{"key":"78_CR90","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","volume":"101","author":"H Mitoma","year":"2018","unstructured":"Mitoma, H., Horiuchi, T., Tsukamoto, H. & Ueda, N. Molecular mechanisms of action of anti-TNF-\u03b1 agents \u2013 comparison among therapeutic TNF-\u03b1 antagonists. Cytokine 101, 56\u201363 (2018).","journal-title":"Cytokine"},{"key":"78_CR91","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cyto.2004.06.008","volume":"28","author":"S Kirchner","year":"2004","unstructured":"Kirchner, S., Holler, E., Haffner, S., Andreesen, R. & Eissner, G. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 28, 67\u201374 (2004).","journal-title":"Cytokine"},{"key":"78_CR92","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","volume":"7","author":"BJ Scallon","year":"1995","unstructured":"Scallon, B. J., Moore, M. A., Trinh, H., Knight, D. M. & Ghrayeb, J. Chimeric anti-TNF-\u03b1 monoclonal antibody cA2 binds recombinant transmembrane TNF-\u03b1 and activates immune effector functions. Cytokine 7, 251\u2013259 (1995).","journal-title":"Cytokine"},{"key":"78_CR93","first-page":"885","volume":"18","author":"L Xin","year":"2006","unstructured":"Xin, L. et al. Dual regulation of soluble tumor necrosis factor-\u03b1 induced activation of human monocytic cells via modulating transmembrane TNF-\u03b1-mediated \u2018reverse signaling\u2019. Int. J. Mol. Med. 18, 885\u2013892 (2006).","journal-title":"Int. J. Mol. Med."},{"key":"78_CR94","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/00054725-200411000-00015","volume":"10","author":"M Ringheanu","year":"2004","unstructured":"Ringheanu, M. et al. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn\u2019s disease. Inflamm. Bowel Dis. 10, 801\u2013810 (2004).","journal-title":"Inflamm. Bowel Dis."},{"key":"78_CR95","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/ibd.22853","volume":"18","author":"G Toedter","year":"2012","unstructured":"Toedter, G. et al. Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy. Inflamm. Bowel Dis. 18, 1399\u20131410 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"78_CR96","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ibd.21818","volume":"18","author":"ACW Vos","year":"2012","unstructured":"Vos, A. C. W. et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm. Bowel Dis. 18, 401\u2013408 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"78_CR97","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2016.01.001","volume":"159","author":"CM Olesen","year":"2016","unstructured":"Olesen, C. M., Coskun, M., Peyrin-Biroulet, L. & Nielsen, O. H. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacol. Ther. 159, 110\u2013119 (2016).","journal-title":"Pharmacol. Ther."},{"key":"78_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012893.pub2","author":"H Yamazaki","year":"2019","unstructured":"Yamazaki, H. et al. Certolizumab pegol for induction of remission in Crohn\u2019s disease. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD012893.pub2 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"key":"78_CR99","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/MIB.0b013e318280b169","volume":"19","author":"N Ueda","year":"2013","unstructured":"Ueda, N. et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor \u03b1. Inflamm. Bowel Dis. 19, 1224\u20131231 (2013).","journal-title":"Inflamm. Bowel Dis."},{"key":"78_CR100","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G. & Tak, P. P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117, 244\u2013279 (2008).","journal-title":"Pharmacol. Ther."},{"key":"78_CR101","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","volume":"6","author":"Q Guo","year":"2018","unstructured":"Guo, Q. et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 6, 15 (2018).","journal-title":"Bone Res."},{"key":"78_CR102","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1172\/JCI36389","volume":"118","author":"FM Brennan","year":"2008","unstructured":"Brennan, F. M. & McInnes, I. B. Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Invest. 118, 3537\u20133545 (2008).","journal-title":"J. Clin. Invest."},{"key":"78_CR103","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cyto.2010.10.010","volume":"53","author":"F Calmon-Hamaty","year":"2011","unstructured":"Calmon-Hamaty, F., Combe, B., Hahne, M. & Morel, J. Lymphotoxin \u03b1 stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts. Cytokine 53, 207\u2013214 (2011).","journal-title":"Cytokine"},{"key":"78_CR104","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1592\/phco.31.1.39","volume":"31","author":"EB Devine","year":"2011","unstructured":"Devine, E. B., Alfonso-Cristancho, R. & Sullivan, S. D. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy 31, 39\u201351 (2011).","journal-title":"Pharmacotherapy"},{"key":"78_CR105","first-page":"2398","volume":"33","author":"G Gartlehner","year":"2006","unstructured":"Gartlehner, G., Hansen, R. A., Jonas, B. L., Thieda, P. & Lohr, K. N. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J. Rheumatol. 33, 2398\u20132408 (2006).","journal-title":"J. Rheumatol."},{"key":"78_CR106","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2147\/DDDT.S115121","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang, S., Zhao, J. & Sun, X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des. Devel. Ther. 10, 1857\u20131867 (2016).","journal-title":"Drug Des. Devel. Ther."},{"key":"78_CR107","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1167\/iovs.04-0601","volume":"46","author":"J Gaudreault","year":"2005","unstructured":"Gaudreault, J., Fei, D., Rusit, J., Suboc, P. & Shiu, V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci. 46, 726\u2013733 (2005).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"78_CR108","first-page":"3025","volume":"53","author":"J Gaudreault","year":"2012","unstructured":"Gaudreault, J. et al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. Invest. Ophthalmol. Vis. Sci. 53, 3025\u20133025 (2012).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"78_CR109","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/bjophthalmol-2014-305149","volume":"99","author":"MK Schmid","year":"2015","unstructured":"Schmid, M. K. et al. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br. J. Ophthalmol. 99, 141\u2013146 (2015).","journal-title":"Br. J. Ophthalmol."},{"key":"78_CR110","first-page":"5616","volume":"58","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y., Chioreso, C., Schweizer, M. L. & Abr\u00e0moff, M. D. Effects of Aflibercept for neovascular age-related macular degeneration: a systematic review and meta-analysis of observational comparative studies. Invest. Ophthalmol. Vis. Sci. 58, 5616\u20135627 (2017).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"78_CR111","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41433-019-0582-0","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma, A., Kumar, N., Kuppermann, B. D., Loewenstein, A. & Bandello, F. Brolucizumab: is extended VEGF suppression on the horizon? Eye 34, 424\u2013426 (2020).","journal-title":"Eye"},{"key":"78_CR112","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel, P. U. et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127, 72\u201384 (2020).","journal-title":"Ophthalmology"},{"key":"78_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.05.038","author":"T Bordet","year":"2019","unstructured":"Bordet, T. & Behar-Cohen, F. Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives. Drug Discov. Today https:\/\/doi.org\/10.1016\/j.drudis.2019.05.038 (2019).","journal-title":"Drug Discov. Today"},{"key":"78_CR114","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","volume":"17","author":"PJ Carter","year":"2018","unstructured":"Carter, P. J. & Lazar, G. A. Next generation antibody drugs: pursuit of the \u2018high-hanging fruit\u2019. Nat. Rev. Drug Discov. 17, 197\u2013223 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78_CR115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.tibtech.2015.10.005","volume":"34","author":"V Neves","year":"2016","unstructured":"Neves, V., Aires-da-Silva, F., Corte-Real, S. & Castanho, M. A. R. B. Antibody approaches to treat brain diseases. Trends Biotechnol. 34, 36\u201348 (2016).","journal-title":"Trends Biotechnol."},{"key":"78_CR116","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","volume":"143","author":"F Erd\u0151","year":"2018","unstructured":"Erd\u0151, F., Bors, L. A., Farkas, D., Bajza, \u00c1. & Gizurarson, S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res. Bull. 143, 155\u2013170 (2018).","journal-title":"Brain Res. Bull."},{"key":"78_CR117","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-23277-7","volume":"8","author":"JS Crowe","year":"2018","unstructured":"Crowe, J. S. et al. Preclinical development of a novel, orally-administered anti-tumour necrosis factor domain antibody for the treatment of inflammatory bowel disease. Sci. Rep. 8, 4941 (2018).","journal-title":"Sci. Rep."},{"key":"78_CR118","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ebiom.2018.07.035","volume":"35","author":"G Burgess","year":"2018","unstructured":"Burgess, G. et al. Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942. EBioMedicine 35, 67\u201375 (2018).","journal-title":"EBioMedicine"},{"key":"78_CR119","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamapsychiatry.2015.22","volume":"72","author":"AH Miller","year":"2015","unstructured":"Miller, A. H. & Raison, C. L. Are anti-inflammatory therapies viable treatments for psychiatric disorders?: Where the rubber meets the road. JAMA Psychiatry 72, 527\u2013528 (2015).","journal-title":"JAMA Psychiatry"},{"key":"78_CR120","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/mp.2016.3","volume":"21","author":"D Goldsmith","year":"2016","unstructured":"Goldsmith, D., Rapaport, M. & Miller, B. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol. Psychiatry 21, 1696\u20131709 (2016).","journal-title":"Mol. Psychiatry"},{"key":"78_CR121","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/s41380-019-0471-8","volume":"25","author":"GM Wittenberg","year":"2020","unstructured":"Wittenberg, G. M. et al. Effects of immunomodulatory drugs on depressive symptoms: a mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. Mol. Psychiatry 25, 1275\u20131285 (2020).","journal-title":"Mol. Psychiatry"},{"key":"78_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.05.002","author":"N Vabret","year":"2020","unstructured":"Vabret, N. et al. Immunology of COVID-19: current state of the science. Immunity https:\/\/doi.org\/10.1016\/j.immuni.2020.05.002 (2020).","journal-title":"Immunity"},{"key":"78_CR123","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"78_CR124","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1021\/ed1003806","volume":"87","author":"NA McGrath","year":"2010","unstructured":"McGrath, N. A., Brichacek, M. & Njardarson, J. T. A graphical journey of innovative organic architectures that have improved our lives. J. Chem. Educ. 87, 1348\u20131349 (2010).","journal-title":"J. Chem. Educ."},{"key":"78_CR125","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrd.2018.14","volume":"17","author":"TI Oprea","year":"2018","unstructured":"Oprea, T. I. et al. Unexplored therapeutic opportunities in the human genome. Nat. Rev. Drug Discov. 17, 317\u2013332 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78_CR126","unstructured":"Malik, A. & Urquhart, L. EvaluatePharma World Preview 2018, outlook to 2024. http:\/\/info.evaluategroup.com\/WP2018-EPV.html (2018)."},{"key":"78_CR127","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/d41573-019-00121-9","volume":"18","author":"L Urquhart","year":"2019","unstructured":"Urquhart, L. FDA new drug approvals in Q2 2019. Nat. Rev. Drug Discov. 18, 575\u2013575 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78_CR128","doi-asserted-by":"crossref","first-page":"D1091","DOI":"10.1093\/nar\/gkx1121","volume":"46","author":"SD Harding","year":"2018","unstructured":"Harding, S. D. et al. The IUPHAR\/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 46, D1091\u2013D1106 (2018).","journal-title":"Nucleic Acids Res."},{"key":"78_CR129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/imr.12392","volume":"270","author":"T Igawa","year":"2016","unstructured":"Igawa, T., Haraya, K. & Hattori, K. Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation. Immunol. Rev. 270, 132\u2013151 (2016).","journal-title":"Immunol. Rev."},{"key":"78_CR130","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd3478","volume":"10","author":"M Rask-Andersen","year":"2011","unstructured":"Rask-Andersen, M., Alm\u00e9n, M. S. & Schi\u00f6th, H. B. Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov. 10, 579\u2013590 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78_CR131","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074\u2013D1082 (2018).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-020-0078-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-020-0078-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-020-0078-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T23:34:44Z","timestamp":1733960084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-020-0078-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":131,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["78"],"URL":"https:\/\/doi.org\/10.1038\/s41573-020-0078-4","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,2]]},"assertion":[{"value":"6 July 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M. R.-A. has performed consulting services for Olink Proteomics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}